Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review

We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.

Automated summary

This article presents a case of pyoderma gangrenosum (PG) caused by secukinumab and successfully treated with risankizumab. The literature review indicates that IL-23 may play a significant role in the pathogenesis of PG, suggesting IL-23-targeting therapies as a potential treatment option for PG.